Full Year 2022 Oxford Nanopore Technologies PLC Earnings Call Transcript
Good afternoon, and welcome to our 2022 full-year results presentation. I'm Gordon Sanghera, Chief Exec of Oxford Nanopore, and I have with me today Tim Cowper, our CFO. I will provide a short summary of our financial highlights for 2022 and key business highlights for the year. Tim will then walk you through our financials in more detail.
The company's vision is to enable the analysis of anything by anyone anywhere. This slide shows an overview of the company, a summary of the company. I will leave you to read that at your leisure. I would like to move directly to the results summary.
We saw continued momentum in our business in 2022. Our total revenues for 2022 were GBP198.6 million. This included a GBP51.8 million one-off legacy COVID testing LamPORE revenue DHSC contract settlement. The core life science research tools revenue was GBP146.8 million. Overall growth, including EGP and COVID sequencing, was 16%. Excluding EGP and COVID sequencing and currency, the underlying growth was 30%.
A key metric for our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
